Literature DB >> 22434430

AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.

Yon Hui Kim1, Han Liang2, Xiuping Liu1, Ju-Seog Lee3, Jae Yong Cho4, Jae-Ho Cheong5, Hoguen Kim6, Min Li7, Thomas J Downey7, Matthew D Dyer8, Yongming Sun8, Jingtao Sun8, Ellen M Beasley8, Hyun Cheol Chung4, Sung Hoon Noh5, John N Weinstein2, Chang-Gong Liu1, Garth Powis1.   

Abstract

Gastric cancer is the most common cancer in Asia and most developing countries. Despite the use of multimodality therapeutics, it remains the second leading cause of cancer death in the world. To identify the molecular underpinnings of gastric cancer in the Asian population, we applied an RNA-sequencing approach to gastric tumor and noncancerous specimens, generating 680 million informative short reads to quantitatively characterize the entire transcriptome of gastric cancer (including mRNAs and miRNAs). A multilayer analysis was then developed to identify multiple types of transcriptional aberrations associated with different stages of gastric cancer, including differentially expressed mRNAs, recurrent somatic mutations, and key differentially expressed miRNAs. Through this approach, we identified the central metabolic regulator AMP-activated protein kinase (AMPK)α as a potential functional target in Asian gastric cancer. Furthermore, we experimentally showed the translational relevance of this gene as a potential therapeutic target for early-stage gastric cancer in Asian patients. Together, our findings not only provide a valuable information resource for identifying and elucidating the molecular mechanisms of Asian gastric cancer, but also represent a general integrative framework to develop more effective therapeutic targets. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434430      PMCID: PMC3872998          DOI: 10.1158/0008-5472.CAN-11-3870

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Authors:  Manish A Shah; Ramesh K Ramanathan; David H Ilson; Alissa Levnor; David D'Adamo; Eileen O'Reilly; Archie Tse; Robin Trocola; Lawrence Schwartz; Marinela Capanu; Gary K Schwartz; David P Kelsen
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

Review 2.  Embracing the complexity of genomic data for personalized medicine.

Authors:  Mike West; Geoffrey S Ginsburg; Andrew T Huang; Joseph R Nevins
Journal:  Genome Res       Date:  2006-05       Impact factor: 9.043

3.  Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress.

Authors:  Rintaro Okoshi; Toshinori Ozaki; Hideki Yamamoto; Kiyohiro Ando; Nami Koida; Sayaka Ono; Tadayuki Koda; Takehiko Kamijo; Akira Nakagawara; Harutoshi Kizaki
Journal:  J Biol Chem       Date:  2007-12-04       Impact factor: 5.157

Review 4.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Authors:  Christos Sotiriou; Martine J Piccart
Journal:  Nat Rev Cancer       Date:  2007-07       Impact factor: 60.716

5.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

6.  Mapping and quantifying mammalian transcriptomes by RNA-Seq.

Authors:  Ali Mortazavi; Brian A Williams; Kenneth McCue; Lorian Schaeffer; Barbara Wold
Journal:  Nat Methods       Date:  2008-05-30       Impact factor: 28.547

7.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

8.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

Authors:  C Pinto; F Di Fabio; S Siena; S Cascinu; F L Rojas Llimpe; C Ceccarelli; V Mutri; L Giannetta; S Giaquinta; C Funaioli; R Berardi; C Longobardi; E Piana; A A Martoni
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

Review 9.  Defining the role of mTOR in cancer.

Authors:  David A Guertin; David M Sabatini
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  52 in total

Review 1.  Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.

Authors:  Biplab Dasgupta; Rishi Raj Chhipa
Journal:  Trends Pharmacol Sci       Date:  2015-12-20       Impact factor: 14.819

2.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

3.  AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27.

Authors:  Stavros Kopsiaftis; Katie L Sullivan; Isha Garg; John A Taylor; Kevin P Claffey
Journal:  Mol Cancer Res       Date:  2016-09-16       Impact factor: 5.852

4.  Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity.

Authors:  S Zhang; Q Qi; C B Chan; W Zhou; J Chen; H R Luo; C Appin; D J Brat; K Ye
Journal:  Cell Death Differ       Date:  2015-05-22       Impact factor: 15.828

5.  A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

Authors:  Junfeng Xia; Peilin Jia; Katherine E Hutchinson; Kimberly B Dahlman; Douglas Johnson; Jeffrey Sosman; William Pao; Zhongming Zhao
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

6.  AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.

Authors:  Brandon Faubert; Gino Boily; Said Izreig; Takla Griss; Bozena Samborska; Zhifeng Dong; Fanny Dupuy; Christopher Chambers; Benjamin J Fuerth; Benoit Viollet; Orval A Mamer; Daina Avizonis; Ralph J DeBerardinis; Peter M Siegel; Russell G Jones
Journal:  Cell Metab       Date:  2012-12-27       Impact factor: 27.287

Review 7.  Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome.

Authors:  Sun Min Lim; Jae Yun Lim; Jae Yong Cho
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

8.  Interpreting personal transcriptomes: personalized mechanism-scale profiling of RNA-seq data.

Authors:  Alan Perez-Rathke; Haiquan Li; Yves A Lussier
Journal:  Pac Symp Biocomput       Date:  2013

Review 9.  Hypothalamic AMPK: a canonical regulator of whole-body energy balance.

Authors:  Miguel López; Rubén Nogueiras; Manuel Tena-Sempere; Carlos Diéguez
Journal:  Nat Rev Endocrinol       Date:  2016-05-20       Impact factor: 43.330

10.  Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.

Authors:  Zhi-Yuan Fan; Wentao Liu; Chao Yan; Zheng-Lun Zhu; Wei Xu; Jian-Fang Li; Liping Su; Chen Li; Zheng-Gang Zhu; Bingya Liu; Min Yan
Journal:  Tumour Biol       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.